You are here: Industry Insights > BMS

News List

US approves new use for BMS’ Empliciti pharmatimes
November 08, 2018
US regulators have expanded the treatment scope of Bristol-Myers Squibb’s Empliciti allowing its use plus pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received
BMS, Pfizer's fast-growing Eliquis is about to steamroll market-leader warfarin: executive fiercepharma
July 31, 2018
Last year, Pfizer and Bristol-Myers Squibb’s Eliquis replaced Johnson & Johnson’s Xarelto as the leader of the novel oral anticoagulant class. And now it’s about to unseat an even bigger foe: warfarin.
BMS and Tsinghua University enter clinical research collaboration pharmaceutical-technology
July 27, 2018
Bristol-Myers Squibb (BMS) has signed a clinical research alliance with Chinese Tsinghua University to facilitate the discovery of drug candidates with new autoimmune disease and cancer targets.
BMS ties with Janssen on Factor XIa inhibitor programme pharmatimes
July 16, 2018
Bristol-Myers Squibb and Johnson & Johnson group Janssen have announced a deal to work together on a Factor XIa (FXIa) inhibitor programme, aiming to reduce the risk of vascular events without increasing the risk of bleeding in patients with thrombotic di
BMS’ Opdivo/Yervoy combo cleared for kidney cancer pharmatimes
July 16, 2018
US regulators have approved a combination of Bristol-Myers Squibb’s immunotherapy drugs Opdivo and Yervoy as a first-line treatment for patients with advanced renal cell carcinoma.
BMS’ Sprycel secures European nod to treat Ph+ CML pharmaceutical-technology
July 12, 2018
Bristol-Myers Squibb (BMS) has secured approval from the European Commission (EC) for the use of its Sprycel (dasatinib) to treat Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML).
Cadila scores FDA approval for BMS and Alvogen generics pharmafile
July 06, 2018
The India-based company will manufacture nifedipine ER, a generic equivalent of Alvogen’s Adolat, at its Moraiya manufacturing facility in Gujurat, India.
NICE turns down BMS' blockbuster Opdivo for urothelial carcinoma pharmafile
July 06, 2018
Just in time for the NHS’ 70th birthday, UK watchdog NICE has announced that it has taken the decision to reject Bristol-Myers Squibb’s blockbuster immunotherapy drug Opdivo (nivolumab) for use on the health service in the treatment of locally advanced un
Final NICE no for BMS’ Opdivo in urothelial carcinoma pharmatimes
July 05, 2018
The National Institute for Health and Care Excellence has now issued final guidance rejecting NHS funding for use of Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC).
FDA accepts BMS’s application for non-small cell lung cancer treatment pharmaceutical-technology
June 28, 2018
The US Food and Drug Administration (FDA) has accepted Bristol-Myers Squibb Company’s (BMY) supplemental biologics licence application (sBLA) for Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) to treat first-line advanced non-small cell lung cancer

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page